Cited by 222Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

Open access

Rowe, Christopher C., Bourgeat, Pierrick, Ellis, Kathryn A., Brown, Belinda, Lim, Yen Ying, Mulligan, Rachel, Jones, Gareth, Maruff, Paul, Woodward, Michael, Price, Roger, Robins, Peter, Tochon‐Danguy, Henri, O'Keefe, Graeme, Pike, Kerryn E., Yates, Paul, Szoeke, Cassandra, Salvado, Olivier, Macaulay, S. Lance, O'Meara, Timothy, Head, Richard, Cobiac, Lynne, Savage, Greg, Martins, Ralph, Masters, Colin L., Ames, David, Villemagne, Victor L.·2013·Annals of Neurology

DOI 10.1002/ana.24040

Open this paper in CoChat — free account Open PDF

Abstract

Objective: Biomarkers for Alzheimer disease (AD) can detect the disease pathology in asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their cognitive prognosis remains uncertain. We aimed to determine the prognostic value of β‐amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals. Methods: A total of 183 healthy individuals (age = 72.0 ± 7.26 years) and 87 participants with MCI (age = 73.7 ± 8.27) in the Australian Imaging, Biomarkers, and Lifestyle study of ageing were studied. Clinical reclassification was performed after 3 years, blind to biomarker findings. β‐Amyloid imaging was considered positive if the 11 C‐Pittsburgh compound B cortical to reference ratio was ≥1.5. Results: Thirteen percent of healthy persons progressed (15 to MCI, 8 to dementia), and 59% of the MCI cohort progressed to probable AD. Multivariate analysis showed β‐amyloid imaging as the single variable most strongly associated with progression. Of combinations, subtle memory impairment ( Z score = −0.5 to −1.5) with a positive amyloid scan was most strongly associated with progression in healthy individuals (odds ratio [OR] = 16, 95% confidence interval [CI] = 3.7–68; positive predictive value [PPV] = 50%, 95% CI = 19–81; negative predictive value [NPV] = 94%, 95% CI = 88–98). Almost all amnestic MCI subjects ( Z score ≤ −1.5) with a positive amyloid scan developed AD (OR = ∞; PPV = 86%, 95% CI = 72–95; NPV = 100%, 95% CI = 80–100). Hippocampal atrophy and ε4 status did not add further predictive value. Interpretation: Subtle memory impairment with a positive β‐amyloid scan identifies healthy individuals at high risk for MCI or AD. Clearly amnestic patients with a positive amyloid scan have prodromal AD and a poor prognosis for dementia within 3 years. Ann Neurol 2013;74:905–913

Integrity signals

Registry

Crossref · 10.1002/ana.24040

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citation
Mild cognitive impairment – Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment.
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains
Good, C. D., Johnsrude, I. S., Ashburner, J., Henson, R. N. A., Friston, K. J., & Frackowiak, R. S. J. (2001) · NeuroImage · doi:10.1006/nimg.2001.0786 · Cited by 4,561
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Mild cognitive impairment
Gauthier, S. G., Reisberg, ‌., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Self-citation

Show all 39 references

Research works printed but not linked: 2

Delis DC, 2000, CVLT‐II: California Verbal Learning Test
KlunkWE.Classification of amyloid‐positivity in controls: comparison of objective approaches to visual reads. Paper presented at: Human Amyloid Imaging Conference; April 11 2008; Chicago IL.

Sorted by citations

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citation
Alzheimer's disease
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citation
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Spreading of pathology in neurodegenerative diseases: a focus on human studies
Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 447
Self-citation
Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409
Self-citation
Age, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Vemuri, P., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Machulda, M. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4821 · Cited by 412
Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology
Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J. D., Morris, M. C., & Bush, A. I. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0375-7 · Cited by 372
Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment
Mito, R., Raffelt, D., Dhollander, T., Vaughan, D. N., Tournier, J.-D., Salvado, O., Brodtmann, A., Rowe, C. C., Villemagne, V. L., & Connelly, A. (2018) · Brain · doi:10.1093/brain/awx355 · Cited by 309
Self-citation
The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals
Sperling, R. A., Mormino, E. C., Schultz, A. P., Betensky, R. A., Papp, K. V., Amariglio, R. E., Hanseeuw, B. J., Buckley, R., Chhatwal, J., Hedden, T., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25395 · Cited by 286
Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging
Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads
Thurfjell, L., Lilja, J., Lundqvist, R., Buckley, C. J., Smith, A. P. L., Vandenberghe, R. R., & Sherwin, P. F. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.142109 · Cited by 225
Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting
Roberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223
Current advances in digital cognitive assessment for preclinical Alzheimer's disease
Öhman, F., Hassenstab, J., Berron, D., Schöll, M., & Papp, K. V. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12217 · Cited by 214
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease
Lim, Y. Y., Maruff, P. T., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Szoeke, C. E. I., Martins, R. N., Masters, C. L., et al. (2013) · Brain · doi:10.1093/brain/awt286 · Cited by 219
Self-citation
Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study
Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207
Self-citation
Cognitive impairment and decline in cognitively normal older adults with high amyloid‐β: A meta‐analysis
Baker, J. E., Lim, Y. Y., Pietrzak, R. H., Hassenstab, J. J., Snyder, P. J., Masters, C. L., & Maruff, P. T. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.09.002 · Cited by 214
Self-citation
Dendritic spines provide cognitive resilience against Alzheimer's disease
Boros, B. D., Greathouse, K. M., Gentry, E. G., Curtis, K. A., Birchall, E. L., Gearing, M., & Herskowitz, J. H. (2017) · Annals of Neurology · doi:10.1002/ana.25049 · Cited by 198
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community
Petersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196
Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.004 · Cited by 187
Self-citation
Amyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185
Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease
Zhang, X., Mormino, E. C., Sun, N., Sperling, R. A., Sabuncu, M. R., Yeo, B. T. T., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611073113 · Cited by 174
Cardiovascular Disease and Alzheimer's Disease: The Heart–Brain Axis
Saeed, A., López, O. L., Cohen, A. D., & Reís, S. E. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030780 · Cited by 181
Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease
Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210005 · Cited by 164
Self-citation
Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer’s Disease Patients, Possible Biomarkers for Early Diagnosis
Grimaldi, A., Pediconi, N., Oieni, F., Pizzarelli, R., Rosito, M., Giubettini, M., Santini, T., Limatola, C., Ruocco, G., Ragozzino, D., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00925 · Cited by 153
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R. A., Maruff, P. T., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 144
Self-citation
Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study
Pérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 148
Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Self-citation
Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline
Boyle, P. A., Yang, J., Yu, L., Leurgans, S. E., Capuano, A. W., Schneider, J. A., Wilson, R. S., & Bennett, D. A. (2016) · Brain · doi:10.1093/brain/aww341 · Cited by 132
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis
Kirmess, K. M., Meyer, M. R., Holubasch, M. S., Knapik, S. S., Hu, Y., Jackson, E. N., Harpstrite, S. E., Verghese, P. B., West, T., Fogelman, I., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.05.011 · Cited by 128
APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Pietrzak, R. H., Snyder, P. J., Ames, D. J., Ellis, K. A., Harrington, K., Rembach, A., Martins, R. N., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.123 · Cited by 126
Self-citation
Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 125
Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer’s Disease
Mormino, E. C., & Papp, K. V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179928 · Cited by 124
Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study
Deters, K., Napolioni, V., Sperling, R. A., Greicius, M. D., Mayeux, R. P., Hohman, T. J., & Mormino, E. C. (2021) · Neurology · doi:10.1212/wnl.0000000000011599 · Cited by 118
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Self-citation
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease
Johnson, P., Vandewater, L., Wilson, W. J., Maruff, P. T., Savage, G. R., Graham, P. L., Macaulay, L. S., Ellis, K. A., Szoeke, C. E. I., Martins, R. N., et al. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s16-s11 · Cited by 112
Self-citation
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Comparison of 18F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL® approaches: Validation against histopathology
Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Self-citation
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
Ong, K. T., Villemagne, V. L., Bahar‐Fuchs, A., Lamb, F., Langdon, N., Catafau, A. M., Stephens, A. W., Seibyl, J. P., Dinkelborg, L. M., Reininger, C. B., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308094 · Cited by 100
Self-citation
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z‐scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score
Lim, Y. Y., Snyder, P. J., Pietrzak, R. H., Ukiqi, A., Villemagne, V. L., Ames, D. J., Salvado, O., Bourgeat, P., Martins, R. N., Masters, C. L., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.003 · Cited by 106
Self-citation
Dendritic spine remodeling accompanies Alzheimer's disease pathology and genetic susceptibility in cognitively normal aging
Boros, B. D., Greathouse, K. M., Gearing, M., & Herskowitz, J. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.003 · Cited by 90
Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment
Wolk, D. A., Sadowsky, C., Safirstein, B., Rinne, J. O., Duara, R., Perry, R. J., Agronin, M., Gamez, J., Shi, J., Ivanoiu, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0894 · Cited by 89
Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease
Lim, Y. Y., Kalinowski, P., Pietrzak, R. H., Laws, S. M., Burnham, S. C., Ames, D. J., Villemagne, V. L., Fowler, C. J., Rainey‐Smith, S. R., Martins, R. N., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4325 · Cited by 87
Self-citation
Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing
Pietrzak, R. H., Lim, Y. Y., Ames, D. J., Harrington, K., Restrepo, C., Martins, R. N., Rembach, A., Laws, S. M., Masters, C. L., Villemagne, V. L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.015 · Cited by 88
Self-citation
Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation
Ekblad, L. L., Johansson, J. J., Helin, S., Viitanen, M. H., Laine, H. K., Puukka, P. J., Jula, A., & Rinne, J. O. (2018) · Neurology · doi:10.1212/wnl.0000000000005214 · Cited by 89
Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals
van der Kall, L. M., Truong, T. H., Burnham, S. C., Doré, V., Mulligan, R. S., Bozinovski, S., Lamb, F., Bourgeat, P., Fripp, J., Schultz, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011222 · Cited by 84
Self-citation
Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update
Farid, K., Charidimou, A., & Baron, J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.05.002 · Cited by 86
APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Snyder, P. J., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.008 · Cited by 85
Self-citation
Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI)
Nathan, P. J., Lim, Y. Y., Abbott, R., Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Bartrés‐Faz, D., Didic, M., Farotti, L., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.013 · Cited by 82
Self-citation
BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer’s disease
Lim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., Maruff, P., Snyder, P. J., Masters, C. L., Allegri, R., et al. (2016) · Brain · doi:10.1093/brain/aww200 · Cited by 76
Self-citation
CenTauR: Toward a universal scale and masks for standardizing tau imaging studies
Villemagne, V. L., Leuzy, A., Bohorquez, S. M. S., Bullich, S., Shimada, H., Rowe, C. C., Bourgeat, P., Lopresti, B. J., Huang, K., Krishnadas, N., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12454 · Cited by 72
Self-citation
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Chiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 75
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 78
Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes
Schreiber, S., Landau, S. M., Fero, A., Schreiber, F., & Jagust, W. J. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1633 · Cited by 79
Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease
Lim, Y. Y., Maruff, P. T., Schindler, R. J., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Santos, C. Y., & Snyder, P. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.009 · Cited by 78
Self-citation
Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias
Nasrallah, I. M., & Wolk, D. A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.141416 · Cited by 76
Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease
The Australian Imaging, B. A. L. (. S., Gu, B. J., Huang, X., Ou, A., Rembach, A., Fowler, C. J., Avula, P. K., Horton, A., Doecke, J. D., Villemagne, V. L., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1596-3 · Cited by 68
Self-citation
Predictive Accuracy of Amyloid Imaging for Progression From Mild Cognitive Impairment to Alzheimer Disease With Different Lengths of Follow-up
Ma, Y., Zhang, S., Li, J., Zheng, D., Guo, Y., Feng, J., & Ren, W.-D. (2014) · Medicine · doi:10.1097/md.0000000000000150 · Cited by 73
A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 71
The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update
Hendrix, J. A., Finger, B., Weiner, M. W., Frisoni, G. B., Iwatsubo, T., Rowe, C. C., Kim, S. Y., Guinjoan, S. M., Sevlever, G. E., & Carrillo, M. C. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.008 · Cited by 65
Self-citation
Deep Learning with Neuroimaging and Genomics in Alzheimer’s Disease
Lin, E., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157911 · Cited by 71
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
Self-citation
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
Stockmann, J., Verberk, I. M. W., Timmesfeld, N., Denz, R., Budde, B., Lange-Leifhelm, J., Scheltens, P., van der Flier, W. M., Nabers, A., Teunissen, C. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00738-8 · Cited by 62
Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit
Molinuevo, J. L., Camı́, J., Carné, X., Carrillo, M. C., Georges, J., Isaac, M., Khachaturian, Z. S., Kim, S. Y. H., Morris, J. C., Pasquier, F., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.009 · Cited by 63
Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer’s disease
Shah, T. M., Gupta, S. M., Chatterjee, P., Campbell, M., & Martins, R. N. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.251 · Cited by 62
Self-citation
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 65
The Full Spectrum of Alzheimer’s Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes
de la Monte, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_4 · Cited by 59
Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study
Porter, T., Burnham, S. C., Milicic, L., Savage, G. R., Maruff, P. T., Lim, Y. Y., Li, Q.-X., Ames, D. J., Masters, C. L., Rainey‐Smith, S. R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180713 · Cited by 59
Self-citation
Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease
Carneiro, P., Morais, S., & Pereira, M. D. C. (2020) · Talanta · doi:10.1016/j.talanta.2019.120700 · Cited by 59
Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk
Jack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac017 · Cited by 59
Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease
Samaroo, A. H., Amariglio, R. E., Burnham, S. C., Sparks, P., Properzi, M. J., Schultz, A. P., Buckley, R. F., Johnson, K. A., Sperling, R. A., Rentz, D. M., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12132 · Cited by 49
Physical Activity in Preventing Alzheimer’s Disease and Cognitive Decline: A Narrative Review
Brini, S., Sohrabi, H. R., Peiffer, J. J., Karrasch, M., Hämäläinen, H., Martins, R. N., & Fairchild, T. J. (2017) · Sports Medicine · doi:10.1007/s40279-017-0787-y · Cited by 62
Self-citation
Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography
Brown, B. M., Rainey‐Smith, S. R., Doré, V., Peiffer, J. J., Burnham, S. C., Laws, S. M., Taddei, K., Ames, D. J., Masters, C. L., Rowe, C. C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170998 · Cited by 52
Self-citation
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A. K., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 56
Self-citation
Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology
Diouf, I., Fazlollahi, A., Bush, A. I., & Ayton, S. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.010 · Cited by 72
Aβ and tau structure‐based biomarkers for a blood‐ and CSF‐based two‐step recruitment strategy to identify patients with dementia due to Alzheimer's disease
Nabers, A., Hafermann, H., Wiltfang, J., & Gerwert, K. B. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.008 · Cited by 47
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 55
Self-citation
Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A Accumulation in Cognitively Normal Older Adults and Adults with MCI
Lim, Y. Y., Pietrzak, R. H., Bourgeat, P., Ames, D. J., Ellis, K. A., Rembach, A., Harrington, K., Salvado, O., Martins, R. N., Snyder, P. J., et al. (2014) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acu068 · Cited by 50
Self-citation
Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer’s disease prediction
Gao, X. R., Chiariglione, M., Qin, K., Nuytemans, K., Scharre, D. W., Li, Y.-J., & Martin, E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-27551-1 · Cited by 45
β-amyloid: The known unknowns
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Amyloid PET imaging in clinical practice
Kolanko, M., Win, Z., Loreto, F., Patel, N., Carswell, C. J., Gontsarova, A., Perry, R. J., & Malhotra, P. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 47
The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations
Mormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
A Modified Bio-Inspired Optimizer with Capsule Network for Diagnosis of Alzheimer Disease
Ganesan, P., Ramesh, G. P., Puttamdappa, C., & Yarlagadda, A. (2024) · Applied Sciences · doi:10.3390/app14156798 · Cited by 40
Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months
Thai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D. J., Ellis, K. A., Rainey‐Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Self-citation
Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice
Guerra, U. P., Nobili, F. M., Padovani, A., Perani, D., Pupi, A., Sorbi, S., & Trabucchi, M. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2079-3 · Cited by 38
Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology
Diouf, I., Bush, A. I., & Ayton, S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104810 · Cited by 38
Aβ-related memory decline in APOE ε4 noncarriers
Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Porter, T., Ames, D. J., Fowler, C. J., Rainey‐Smith, S. R., Snyder, P. J., Martins, R. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002604 · Cited by 39
Self-citation
KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden
Porter, T., Burnham, S. C., Doré, V., Savage, G. R., Bourgeat, P., Begemann, K., Milicic, L., Ames, D. J., Bush, A. I., Maruff, P. T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20513-y · Cited by 36
Self-citation
Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract
Chu, W. T., Wang, W., Záborszky, L., Golde, T. E., DeKosky, S. T., Duara, R., Loewenstein, D., Adjouadi, M., Coombes, S. A., & Vaillancourt, D. E. (2021) · Neurology · doi:10.1212/wnl.0000000000013206 · Cited by 36
In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data
Mito, R., Dhollander, T., Xia, Y., Raffelt, D. A., Salvado, O., Churilov, L. P., Rowe, C. C., Brodtmann, A. G., Villemagne, V. L., & Connelly, A. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102479 · Cited by 37
Self-citation
The role of positron emission tomography imaging in understanding Alzheimer’s disease
Barthel, H., Seibyl, J. P., & Sabri, O. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1023296 · Cited by 34
The Healthy Brain Project: An Online Platform for the Recruitment, Assessment, and Monitoring of Middle-Aged Adults at Risk of Developing Alzheimer’s Disease
Lim, Y. Y., Yassi, N., Bransby, L., Properzi, M. J., & Buckley, R. F. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181139 · Cited by 36
Self-citation
Disrupted topology of the resting state structural connectome in middle-aged APOE ε4 carriers
Korthauer, L. E., Zhan, L., Ajilore, O., Leow, A., & Driscoll, I. F. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.05.052 · Cited by 31
Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals
McRae‐McKee, K., Evans, S., Hadjichrysanthou, C., Wong, M. M., de Wolf, F., & Anderson, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42632-w · Cited by 32
Predicting Alzheimer disease from a blood-based biomarker profile
Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., Laws, S. M., Martins, R. N., Maruff, P. T., Macaulay, S. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003094 · Cited by 34
Self-citation
Neuropsychology and neuroimaging profiles of amyloid‐positive versus amyloid‐negative amnestic mild cognitive impairment patients
Tomadesso, C., Sayette, V. D. L., de Florès, R., Bourgeat, P., Villemagne, V. L., Egret, S., Eustache, F., & Chételat, G. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.02.008 · Cited by 30
Self-citation
Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment
Kandel, B. M., Avants, B., Gee, J. C., Arnold, S. E., Wolk, D. A., & Initiative, A. D. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142943 · Cited by 29

Authors: Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., Robins, P., Tochon‐Danguy, H., O'Keefe, G., Pike, K. E., Yates, P., Szoeke, C., Salvado, O., Macaulay, S. L., O'Meara, T., Head, R., Cobiac, L., Savage, G., Martins, R., Masters, C. L., Ames, D., & Villemagne, V. L.
Affiliations: Austin Health (AU)
Australian e-Health Research Centre (AU)
The University of Melbourne (AU)
Edith Cowan University (AU)
Sir Charles Gairdner Hospital (AU)
La Trobe University (AU)
National Ageing Research Institute (AU)
Commonwealth Scientific and Industrial Research Organisation (AU)
Australian Research Council (AU)
Corresponding author: Rowe, Christopher C.
ORCID: Rowe, Christopher C.
Bourgeat, Pierrick
Ellis, Kathryn A.
Brown, Belinda
Lim, Yen Ying
Jones, Gareth
Maruff, Paul
O'Keefe, Graeme
Pike, Kerryn E.
Yates, Paul
Szoeke, Cassandra
Salvado, Olivier
Macaulay, S. Lance
Head, Richard
Savage, Greg
Martins, Ralph
Masters, Colin L.
Villemagne, Victor L.
Venue: Annals of Neurology
Publisher: Wiley
Published: 2013-12
Volume: 74
Issue: 6
Pages: 905-913
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.24040
OpenAlex: W2003569140
Cited by: 222
References: 39
Citations by year: 2026: 5 · 2025: 7 · 2024: 9 · 2023: 15 · 2022: 19 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 34 · 2017: 13 · 2016: 19 · 2015: 19 · 2014: 17 · 2013: 1
FWCI: 13.27
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0/ (vor, 51 d)
Locations: Annals of Neurology (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Research Bank (Australian Catholic University) (submittedVersion)
Murdoch University Research Portal (submittedVersion)
Australasian Journal of Paramedicine (submittedVersion, cc-by-nc)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, other-oa)
Griffith Research Online (submittedVersion, cc-by-nc)
Funders: Commonwealth Scientific Industrial Research Organization (CSIRO)
Science Industry Endowment Fund
National Health and Medical Research Council of Australia (1011689)
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: Alzheimer's disease, amyloid-beta imaging, Pittsburgh compound B, mild cognitive impairment, amnestic MCI, dementia progression, prodromal Alzheimer's disease, memory impairment, hippocampal atrophy, APOE ε4, predictive value, non-demented elderly
MeSH terms: Aged, Aged, 80 and over, Aging, Alzheimer Disease, Apolipoproteins E, Atrophy, Australia, Female, Hippocampus, Humans, Life Style, Male, Memory Disorders, Middle Aged, Predictive Value of Tests, Biomarkers, Single-Blind Method, Amyloid beta-Peptides, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks